# Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

> **NCT02957396** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Finerenone (BAY94-8862): 20 mg intact tablet
- **DRUG:** Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet
- **DRUG:** Finerenone (BAY94-8862): 20 mg suspension

## Key facts

- **NCT ID:** NCT02957396
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-17
- **Primary completion:** 2017-01-13
- **Final completion:** 2017-03-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957396, "Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02957396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*